Core Viewpoint - The inclusion of药捷安康-B (02617) in the Hang Seng Composite Index is expected to enhance its visibility and liquidity in the market, with potential adjustments to the Hong Kong Stock Connect investment scope [1] Group 1: Company Developments -药捷安康-B has been included in the Hang Seng Composite Index, with the change effective from September 8, 2025, following the announcement on August 22 [1] - The company’s self-developed multi-target kinase inhibitor,替恩戈替尼 (TT-00420), has received Fast Track designation from the FDA for the treatment of metastatic castration-resistant prostate cancer [1] -替恩戈替尼 is currently in global Phase III registration trials, targeting FGFR/VEGFR, JAK, and Aurora kinases for its anti-tumor effects, showing potential efficacy in treating various solid tumors in ongoing clinical trials in the US and China [1] Group 2: Market Implications - The inclusion in the Hang Seng Composite Index may lead to an increase in the stock's market capitalization and liquidity, as it meets criteria such as market value, liquidity, and listing duration [1] - There is a possibility that药捷安康-B could be added to the Hong Kong Stock Connect, further broadening its investor base [1]
药捷安康-B获纳入恒生综合指数 有望成为港股通标的